Process for preparing a pharmaceutical formulation of contrast agents

Patent metadata

Field	Value
Publication number	US-9655983-B2
Application number	US-91825909-A
Country	US
Kind code	B2
Filing date	Feb 18, 2009
Priority date	Feb 19, 2008
Publication date	May 23, 2017
Grant date	May 23, 2017

Abstract

The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate C ch1 and/or of free lanthanide C lan1; d) adjustment of C ch1 and/or of C lan1 so as to obtain C ch1=C tch1 and C lan1=0, wherein C t ch1 is the target concentration of free macrocyclic chelate in the final liquid pharmaceutical formulation.

First claim

The invention claimed is:

1. An industrial process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, wherein the process comprises the following successive steps:
(b) preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide, and:
free lanthanide,
and optionally free macrocyclic chelate;
said step (b) consisting of mixing a solution of free macrocyclic chelate and free lanthanide wherein the lanthanide/macrocyclic chelate mol/mol ratio is between 1.001 and 1.3;
(c1) adjusting the pH of a sample of the liquid pharmaceutical formulation obtained in step (b) so that the concentration of free macrocyclic chelate C ch 1 is equal to 0;
(c2) measuring in the sample of the liquid pharmaceutical formulation obtained in step (c1) the concentration of free lanthanide C lan 1 ;
(d) adjusting the concentration of free macrocyclic chelate C ch 1 in the liquid pharmaceutical formulation based on the measurements obtained in step (c2) by adding to the formulation obtained in step (b) the amount of free macrocyclic chelate necessary to complete the complexation of the free lanthanide so as to obtain C lan 1 =0, and to obtain C ch 1 =C t ch 1 , wherein C t ch 1 is the target concentration of the free macrocyclic chelate in the final liquid pharmaceutical formulation and is between 0.002% and 0.4%, and adjusting the pH of the final liquid pharmaceutical formulation with meglumine;
wherein the amount of free macrocyclic chelate in the final liquid pharmaceutical formulation corresponds to the proportion of free macrocyclic chelate relative to the amount of complexed macrocyclic chelate in the final liquid pharmaceutical formulation;
wherein the complex of macrocyclic chelate with a lanthanide is the meglumine salt of the DOTA-gadolinium complex, the macrocyclic chelate is DOTA and the lanthanide is gadolinium;
wherein the operating steps (b) and (d) of the process occur in the same reactor; and
wherein the liquid pharmaceutical formulation is an injectable solution.

2. Process according to claim 1 , wherein any calcium present in the final liquid pharmaceutical formulation is present in an amount of less than 50 ppm.

3. Process according to claim 2 , wherein the amount of calcium present in the final liquid pharmaceutical formulation is less than 20 ppm.

4. Process according to claim 3 , wherein the amount of calcium present in the final liquid pharmaceutical formulation is less than 5 ppm.

5. Process according to claim 2 , wherein the liquid pharmaceutical formulation is prepared from ingredients including chelate powder, water and meglumine, and wherein the amount of calcium in the ingredients used to prepare the final liquid pharmaceutical formulation is less than 50 ppm.

6. Process according to claim 2 , wherein it comprises, before step (c1), an intermediate step (b2) of measuring the amount of calcium in the obtained solution, and removing any excess calcium in order to obtain an amount of less than 50 ppm in said solution.

7. Process according to claim 1 , further comprising as step (e) the step of checking concentrations C ch 1 and C lan 1 after step (d).

8. Process according to claim 1 , wherein the mol/mol amount of free macrocyclic chelate is between 0.025% and 0.25%.

9. Process according to claim 1 , wherein step (b) is carried out at a temperature of between 60° C. and 100° C.

10. The process of claim 1 , wherein gadolinium is added as gadolinium oxide in step (b).

11. The process of claim 1 , wherein said step (b) consists of mixing a solution of free macrocyclic chelate and free lanthanide for 1 to 3 hours at a pH of between 4 and 7.

12. The process of claim 1 , wherein step (d) comprises adjusting the pH of the final liquid pharmaceutical formulation with meglumine to between 6.5 and 7.5.

13. An industrial process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, wherein the process comprises the following successive steps:
(b) preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide, and:
free lanthanide,
and optionally free macrocyclic chelate;
said step (b) consisting of mixing a solution of free macrocyclic chelate and free lanthanide for 1 to 3 hours at a temperature between 60° C. and 100° C. at a pH between 4 and 7 wherein the lanthanide/macrocyclic chelate mol/mol ratio is between 1.001 and 1.3;
(c1) adjusting the pH of a sample of the liquid pharmaceutical formulation obtained in step (b) to 7;
(c2) measuring in the sample of the liquid pharmaceutical formulation obtained in step (c1) the concentration of free lanthanide C lan 1 ;
(d) adjusting the concentration of free macrocyclic chelate C ch 1 in the liquid pharmaceutical formulation based on the measurements obtained in step (c2) by adding to the formulation obtained in step (b) the amount of free macrocyclic chelate necessary to complete the complexation of the free lanthanide so as to obtain C lan 1 =0, and to obtain C ch 1 =C t ch 1 , wherein C t ch 1 is the target concentration of the free macrocyclic chelate in the final liquid pharmaceutical formulation and is between 0.002% and 0.4%, and adjusting the pH of the final liquid pharmaceutical formulation with meglumine to between 6.5 and 7.5;
wherein the amount of free macrocyclic chelate in the final liquid pharmaceutical formulation corresponds to the proportion of free macrocyclic chelate relative to the amount of complexed macrocyclic chelate in the final liquid pharmaceutical formulation;
wherein the complex of macrocyclic chelate with a lanthanide is the meglumine salt of the DOTA-gadolinium complex, the macrocyclic chelate is DOTA and the lanthanide is gadolinium; and
wherein the operating steps (b) and (d) of the process occur in the same reactor.

14. The process of claim 1 , wherein in step (c1), the pH is adjusted to 7.

Assignees

• Meyer Dominique
• Corot Claire
• Port Marc
• Barbotin Vincent
• Bonnemain Bruno
• Guerbet Sa

Inventors

• Meyer Dominique
• Corot Claire
• Port Marc
• Barbotin Vincent
• Bonnemain Bruno

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K31/28

  Compounds containing heavy metals · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K49/106

  the complex-forming compound being cyclic, e.g. DOTA · CPC title

• A61K49/108 Primary

  the metal complex being Gd-DOTA · CPC title